Physician profile
Mohammad Atif
NPI 1801457882
$2,089.95
in general payments reported to CMS, 2019-2025
10 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $80.80 · 2022: $221 · 2023: $964 · 2024: $585 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,788.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $552.62 | 2022-2025 | Rybelsus, Ozempic, Tresiba |
| Abbvie INC. | $499.17 | 2023-2024 | Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $469.35 | 2022-2024 | Farxiga, Breztri |
| Abbott Laboratories | $169.25 | 2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.26 | 2025 | |
| Cardiovascular Systems INC. | $80.80 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.21 | 2022-2023 | Jardiance |
| Pfizer INC. | $23.45 | 2022 | |
| Lilly USA, LLC | $14.84 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Atif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.